Eremophila alpestris
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA636570 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR10321519_1.fastq.gz | Fastqsanger.gz | |||
| SRR10321519_2.fastq.gz | Fastqsanger.gz | |||
| SRR10321520_1.fastq.gz | Fastqsanger.gz | |||
| SRR10321520_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 9 |
Similar Datasets
Project description:Eremophila alpestris peregrina isolate:EALPPER07 Genome sequencing and assembly
| PRJNA575884 | ENA
Project description:Plants in the Australian genus Eremophila (Scrophulariaceae) have attracted considerable recent attention for their antimicrobial compounds, which possess a wide range of chemical structures. As they are typically associated with the oily-waxy resin layer covering leaves and green branchlets, and Eremophila lucida is prominent among the species containing a pronounced sticky resin layer, this species was considered of interest for assessing its antibacterial constituents. The n-hexane fraction of the crude acetone extract of the leaves exhibited antibacterial activity against Staphylococcus aureus. Isolation led to the known compounds cembratriene, (3Z, 7E, 11Z)-15-hydroxycembra-3,7,11-trien-19-oic acid (1), the sesquiterpenoid, farnesal (2) and the viscidane diterpenoid, 5α-hydroxyviscida-3,14-dien-20-oic acid (3). The purified compounds were tested for antibacterial activity with 2 and 3 showing moderate antibacterial activity against Gram-positive bacteria.
| S-EPMC6627632 | biostudies-literature
Project description:Spectral data and metadata for the puplication: "Polypharmacology-Labeled Molecular Networking: An Analytical Technology Workflow for Accelerated Identification of Multiple Bioactive Constituents in Complex Extracts" || Yong Zhao, Oliver Gericke, Tuo Li, Louise Kjaerulff, Kenneth T. Kongstad, Allison M. Heskes, Birger L. Moeller, Henrietta Venter, Sonia Coriani, Susan J. Semple, and Dan Staerk* || Bioassay data || Bioassay data includes anti-diabetic and anti-bacterial activity of microfractions from Eremophila rugosa crude leaf extract.The file "Erugosa_bioassay_data.txt" contains bioassay data. Collection of fractions are indicated with retention time: start and end of microfraction collection as well as average collection time. Anti-diabetic bioassays include alpha-glucosidase and PTP1B inhibition in percentage. Anti-microbial bioassays include S. epidermidis, S. aureus, S.aureus MRSA, E.faecium and E.faecium VRE growth inbition in percentage. For comparision, bioassay data was normalized to the largest value observed per assay. These values are indicated in additional columns. || UV data || UV absorbance was determined for wavelengths 210 nm and 280 nm at different retention time points. The file "Erugosa_UV_data.txt" contains UV data. || In silico dereplication through network annotation propagation(NAP) || The file "Erugosa_ISDB.tsv" was used within the NAP workflow on GNPS to achieve an enhanced chemical classification of the studied spectral dataset derived from Eremophila rugosa leaf extract. The file "Erugosa_ISDB.txt" contains the underlying SMILES strings and compound identifiers used to establish this spectral database. The majority of compound names with the identifier "Singab_#" relate to compounds described in Singab et al. 2013 chemical review [1], whereas "KU" compounds are presented within the manuscript. Other compound identifiers used in this study are: Zhao2019_Ebignoniiflora_# [2], BCFA_# [3], Tahtah_# [4], Wubshet_# [5], Bee_Mi_# [6], LK_Mi_# [7], Duke_Mi_# [8].
[1] Singab, A. N., Youssef, F. S., Ashour, M. L., and Wink, M. (2013). The genus Eremophila (Scrophulariaceae): an ethnobotanical, biological and phytochemical review. J. Pharm. Pharmacol. 65, 1239-1279.
[2] Zhao, Y., Kjaerulff, L., Kongstad, K. T., Heskes, A. M., Moeller, B. L., and Staerk, D. (2019). 2(5H)-Furanone sesquiterpenes from Eremophila bignoniiflora: High-resolution inhibition profiling and PTP1B inhibitory activity. Phytochemistry 166, 112054.
[3] Pedersen, H. A., Ndi, C., Semple, S. J., Buirchell, B., Moeller, B. L., and Staerk, D. (2020). PTP1B-Inhibiting Branched-Chain Fatty Acid Dimers from Eremophila oppositifolia subsp. angustifolia Identified by High-Resolution PTP1B Inhibition Profiling and HPLC-PDA-HRMS-SPE-NMR Analysis. J. Nat. Prod.
[4] Tahtah, Y., Wubshet, S. G., Kongstad, K. T., Heskes, A. M., Pateraki, I., Moeller, B. L., et al. (2016). High-resolution PTP1B inhibition profiling combined with high-performance liquid chromatography-high-resolution mass spectrometry-solid-phase extraction-nuclear magnetic resonance spectroscopy: Proof-of-concept and antidiabetic constituents in crude extra. Fitoterapia 110, 52-58.
[5] Wubshet, S. G., Tahtah, Y., Heskes, A. M., Kongstad, K. T., Pateraki, I., Hamberger, B., et al. (2016). Identification of PTP1B and a-Glucosidase Inhibitory Serrulatanes from Eremophila spp. by Combined use of Dual High-Resolution PTP1B and a-Glucosidase Inhibition Profiling and HPLC-HRMS-SPE-NMR. J. Nat. Prod. 79, 1063-1072.
[6] Aminimoghadamfarouj, N., and Nematollahi, A. (2017). Structure Elucidation and Botanical Characterization of Diterpenes from a Specific Type of Bee Glue. Molecules 22, 1185.
[7] Kjaerulff, L., Jensen, A. B. J., Ndi, C., Semple, S., Moeller, B. L., and Staerk, D. (2020). Isolation, structure elucidation and PTP1B inhibitory activity of serrulatane diterpenoids from the roots of Myoporum insulare. Phytochem. Lett. 39, 49-56.
[8] Duke, C. C., Duke, R. K., and Tran, V. H. (2018). Medicinal use of serrulatane diterpenes. Available at: https://patents.google.com/patent/US20190282514A1/en
2021-11-24 | MSV000088442 | GNPS
Project description:Australia's endemic desert shrubs are commonly aromatic, with chemically diverse terpenes and phenylpropanoids in their headspace profiles. Species from the genus Eremophila (Scrophulariaceae ex. Myoporaceae) are the most common, with 215 recognised taxa and many more that have not yet been described, widely spread across the arid parts of the Australian continent. Over the years, our research team has collected multiple specimens as part of a survey to investigate the chemical diversity of the genus and create leads for further scientific enquiry. In the current study, the diversity of volatile compounds is studied using hydrodistilled essential oils and leaf solvent extracts from 30 taxa. Several rare terpenes and iridoids were detected in chemical profiles widely across the genus, and three previously undescribed sesquiterpenes were isolated and are assigned by 2D NMR-E-11(12)-dehydroisodendrolasin, Z-11-hydroxyisodendrolasin and 10-hydroxydihydro-α-humulene acetate. Multiple sampling from Eremophila longifolia, Eremophila arbuscular, Eremophila latrobei, Eremophila deserti, Eremophila sturtii, Eremophila oppositifolia and Eremophila alternifolia coneys that species in Eremophila are highly chemovariable. However, taxa are generally grouped according to the expression of (1) furanosesquiterpenes, (2) iridoids or oxides, (3) mixtures of 1 and 2, (4) phenylpropanoids, (5) non-furanoid terpenes, (6) mixtures of 4 and 5, and less commonly (7) mixtures of 1 and 5. Furthermore, GC-MS analysis of solvent-extracted leaves taken from cultivated specimens conveys that many heavier 'volatiles' with lower vapour pressure are not detected in hydrodistilled essential oils and have therefore been neglected in past chemical studies. Hence, our data reiterate that chemical studies of the genus Eremophila will continue to describe new metabolites and that taxon determination has limited predictive value for the chemical composition.
| S-EPMC8073941 | biostudies-literature
Project description:The genus Eremophila (family Scrophulariaceae) consists of approximately 200 species that are widely distributed in the semi-arid and arid regions of Australia. Multiple Eremophila spp. are used as traditional medicines by the First Australians in the areas in which they grow. They are used for their antibacterial, antifungal, antiviral, antioxidant, anti-diabetic, anti-inflammatory, and cardiac properties. Many species of this genus are beneficial against several diseases and ailments. The antibacterial properties of the genus have been relatively well studied, with several important compounds identified and their mechanisms studied. In particular, Eremophila spp. are rich in terpenoids, and the antimicrobial bioactivities of many of these compounds have already been confirmed. The therapeutic properties of Eremophila spp. preparations and purified compounds have received substantially less attention, and much study is required to validate the traditional uses and to highlight species that warrant further investigation as drug leads. The aim of this study is to review and summarise the research into the medicinal properties, therapeutic mechanisms, and phytochemistry of Eremophila spp., with the aim of focussing future studies into the therapeutic potential of this important genus.
| S-EPMC9697388 | biostudies-literature